drugset / Trial / NCT05058755
Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Natural killer/T-cell lymphoma (NKTCL) patients with relapsed/refractory disease had very poor outcome. Anti-PD-1 antibody showed promising results in response, but but the complete remission rate of was low. Some anti-PD-1 antibody based regimen showed higher and deeper response in NKTCL patients.
Timeline
- Start
- 2021-09-17
- Primary completion
- 2022-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Other |
| Subject | Etoposide | Small molecule | 100 mg | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Pegaspargase | Protein / enzyme biologic | 2000 unknown | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |